We are constantly working to improve the site, and to add more laws to our database. If you are receiving value from using our site please consider signing up for a subscription to support the site and to get many additional benefits for you.
Key Benefits:
(You can close this ad by clicking anywhere on the page.)
Key Benefits:
By Resolution of 2 August 2012, from the General Directorate of the Basic Portfolio of Services of the National System of Health and Pharmacy, the list of drugs that are excluded from the provision was updated. pharmaceutical in the National Health System. This Resolution was drawn up in accordance with the provisions of Article 85.ter.1 of Law 29/2006 of 26 July on the guarantees and rational use of medicinal products and medical devices, which orders the body responsible for the provision of medicinal products to The Ministry of Health, Social Services and Equality will update the list of drugs that are excluded from the pharmaceutical provision in the National Health System.
Paragraph 3 of the Annex to the Resolution provided for exceptions to the exclusion rule for funding in the National Health System in the form of therapeutic subgroups, so that the medicines included in the continue to be prescribed and dispensed with the National Health System when prescribed exclusively for the indications detailed in each case.
Warned in the Resolution of 2 August 2012, of the General Directorate of the Basic Portfolio of Services of the National System of Health and Pharmacy, published in the "Official Gazette of the State" number 197, of August 17, 2012, with regard to the updating of the list of medicinal products which are excluded from the pharmaceutical provision in the National Health System, appropriate corrections should be made.
On page 59190, in point 3. Exceptions, where it says:
|
Group | They are kept included in the SNS pharmaceutical delivery for these indications |
|---|---|
| 1. A06AC | Inflammatory Bowel Disease, irritable colon, and diverticulosis. |
|
2. A06AD | Portosystemic encephalopathy and paraplegia. |
| 3. A06AH | Cancer patients. |
|
4. C04AX | Intermittent clause. |
|
5. R05DA | Neoplastic patients with persistent cough |
|
6. S01XA | Sjögren Syndrome. |
You must say:
|
Group | They are kept included in the SNS pharmaceutical delivery for these indications |
|---|---|
| 1. A06AC | Inflammatory Bowel Disease, irritable colon, and diverticulosis. |
|
2. A06AD | Portosystemic encephalopathy and paraplegia. |
| 3. A06AH | Cancer patients. |
|
4. C04AX | Intermittent clause. |
|
5. C10AX06 | Patients with severe hypertriglyceridemia in which fibrates are contraindicated |
|
6. R05DA | Neoplastic patients with persistent cough |
|
7. S01XA | Alleviation of ocular dryness in patients affected by Sjögren's syndrome. |
Madrid, September 17, 2012. -Director General of the Basic Portfolio of Services of the National System of Health and Pharmacy, Agustín Rivero Cuadrado.
